Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis

Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis - Prospective study for effectiveness of Etelcalcetide on dialysis patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032637

Enrollment

200

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients treated with hemodialysis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treating with hemodialysis for more than 12 months in dialysis clinic in Zenjinkai group

Exclusion criteria

Exclusion criteria: Patients decided as incompetent for this study by the doctor Patietns showing contraindication for PARSABIV Patients showing low Ca(<8.4) before admonistration of PARSABIV Patients having malignant diseases Patients having serious diseases in liver, kidney (other than CRF), and heart. Patients treated with cinacalcet or bisphosphonate

Design outcomes

Primary

Measure	Time frame
Change of QOL (every month)	—

Secondary

Measure	Time frame
Estimation od complication (every month) CTR/ECG (every month) bone mineral density and UCG(1 year later) General blood test (every month) Check of leftover medicine	—

Countries

Japan

Contacts

Public ContactAshio Yoshimura

Zenjinkai Shinyokohama Daiichi Clinic Division of Nephrology

shinyokohd@gmail.com045-477-3412

Outcome results